Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Transition Therapeutics

- PMLiVE

FDA approves new drugs from Teva, Lilly and Elusys

Cinqair, Taltz and Anthim have all been given the green light in the US

Eli Lilly HQ

Lilly’s Lantus ‘follow-on’ approved in the US

Basaglar is first insulin product to be licensed via the FDA's truncated 505(b)(2) pathway

Eli Lilly HQ

Lilly says insulin peglispro too risky to pursue

Discontinues development of medicine once tipped as a diabetes blockbuster

- PMLiVE

Blue Latitude’s industry-first praised at PMEA

Support for Lilly and its Medical Information Cascade wins Innovation Award

Eli Lilly HQ

FDA clears Lilly’s lung cancer drug Portrazza

First biologic drug to be approved as first-line therapy for NSCLC

Eli Lilly HQ

Sanofi and Lilly highlight rheumatoid arthritis hopefuls at ACR

Top-line results for sarilumab and baricitinib

- PMLiVE

US government probes Lilly and Merck over drug pricing

Department of Justice investigates drug pricing with regard to Medicaid programme

Eli Lilly HQ

Lilly and AZ forge closer immuno-oncology bond

Look to boost their presence in a market predicted to be worth $30bn in 10 years

- PMLiVE

Lilly’s baricitinib beats Humira in trial for RA

Posts positive phase III data against the world's biggest-selling drug

- PMLiVE

Lilly drops evacetrapib on failed atherosclerosis trial

Leaves hole in company's late-stage pipeline

Eli Lilly HQ

Lilly acquires rights to intranasal glucagon spray

Could be first needle-less emergency treatment for hypoglycaemia

Eli Lilly HQ

Lilly wins breakthrough designation for breast cancer drug

CDK 4 and 6 inhibitor Abemaciclib's development to be expedited by FDA

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links